Nonsteroidal Anti-inflammatory Drugs Alter the Microbiota and Exacerbate Colitis while Dysregulating the Inflammatory Response
Name:
mBio-2019-Maseda-e02282-18.full.pdf
Size:
3.164Mb
Format:
PDF
Description:
Final Published version
Author
Maseda, DamianZackular, Joseph P
Trindade, Bruno
Kirk, Leslie
Roxas, Jennifer Lising
Rogers, Lisa M
Washington, Mary K
Du, Liping
Koyama, Tatsuki
Viswanathan, V K
Vedantam, Gayatri
Schloss, Patrick D
Crofford, Leslie J
Skaar, Eric P
Aronoff, David M
Affiliation
Univ Arizona, Sch Anim & Comparat Biomed SciIssue Date
2019-01-08Keywords
Clostridium difficilecolitis
gut inflammation
immune dysfunction
immune response
inflammation
intestinal immunity
prostaglandin
Metadata
Show full item recordPublisher
AMER SOC MICROBIOLOGYCitation
Maseda D, Zackular JP, Trindade B, Kirk L, Roxas JL, Rogers LM, Washington MK, Du L, Koyama T, Viswanathan VK, Vedantam G, Schloss PD, Crofford LJ, Skaar EP, Aronoff DM. 2019. Nonsteroidal anti-inflammatory drugs alter the microbiota and exacerbate Clostridium difficile colitis while dysregulating the inflammatory response. mBio 10:e02282-18. https://doi.org/10.1128/mBio.02282-18Journal
MBIORights
Copyright © 2019 Maseda et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Clostridium difficile infection (CDI) is a major public health threat worldwide. The use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with enhanced susceptibility to and severity of CDI; however, the mechanisms driving this phenomenon have not been elucidated. NSAIDs alter prostaglandin (PG) metabolism by inhibiting cyclooxygenase (COX) enzymes. Here, we found that treatment with the NSAID indomethacin prior to infection altered the microbiota and dramatically increased mortality and the intestinal pathology associated with CDI in mice. We demonstrated that in C. difficile-infected animals, indomethacin treatment led to PG deregulation, an altered proinflammatory transcriptional and protein profile, and perturbed epithelial cell junctions. These effects were paralleled by increased recruitment of intestinal neutrophils and CD4+ cells and also by a perturbation of the gut microbiota. Together, these data implicate NSAIDs in the disruption of protective COX-mediated PG production during CDI, resulting in altered epithelial integrity and associated immune responses.IMPORTANCEClostridium difficile infection (CDI) is a spore-forming anaerobic bacterium and leading cause of antibiotic-associated colitis. Epidemiological data suggest that use of nonsteroidal anti-inflammatory drugs (NSAIDs) increases the risk for CDI in humans, a potentially important observation given the widespread use of NSAIDs. Prior studies in rodent models of CDI found that NSAID exposure following infection increases the severity of CDI, but mechanisms to explain this are lacking. Here we present new data from a mouse model of antibiotic-associated CDI suggesting that brief NSAID exposure prior to CDI increases the severity of the infectious colitis. These data shed new light on potential mechanisms linking NSAID use to worsened CDI, including drug-induced disturbances to the gut microbiome and colonic epithelial integrity. Studies were limited to a single NSAID (indomethacin), so future studies are needed to assess the generalizability of our findings and to establish a direct link to the human condition.Note
Open access journalISSN
2150-7511PubMed ID
30622186Version
Final published versionSponsors
Crohn's and Colitis Foundation of America; NIH-NIDDK [T32DK007673]; NIH-NIAID [R21AI121796, F32AI120553]; NIH-NCATS [U01TR002398, R21TR001723]Additional Links
https://mbio.asm.org/content/10/1/e02282-18ae974a485f413a2113503eed53cd6c53
10.1128/mBio.02282-18
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Copyright © 2019 Maseda et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
Related articles
- Indomethacin increases severity of Clostridium difficile infection in mouse model.
- Authors: Muñoz-Miralles J, Trindade BC, Castro-Córdova P, Bergin IL, Kirk LA, Gil F, Aronoff DM, Paredes-Sabja D
- Issue date: 2018 Sep
- Misoprostol protects mice against severe Clostridium difficile infection and promotes recovery of the gut microbiota after antibiotic perturbation.
- Authors: Zackular JP, Kirk L, Trindade BC, Skaar EP, Aronoff DM
- Issue date: 2019 Aug
- Intestinal Inflammation and Altered Gut Microbiota Associated with Inflammatory Bowel Disease Render Mice Susceptible to Clostridioides difficile Colonization and Infection.
- Authors: Abernathy-Close L, Barron MR, George JM, Dieterle MG, Vendrov KC, Bergin IL, Young VB
- Issue date: 2021 Jun 29
- Investigating the impact of antibiotic-induced dysbiosis on protection from Clostridium difficile colitis by mouse colonic innate lymphoid cells.
- Authors: Uddin MJ, Thompson B, Leslie JL, Fishman C, Sol-Church K, Kumar P, Petri WA Jr
- Issue date: 2024 Mar 13
- Intestinal Inflammation Reversibly Alters the Microbiota to Drive Susceptibility to Clostridioides difficile Colonization in a Mouse Model of Colitis.
- Authors: Barron MR, Sovacool KL, Abernathy-Close L, Vendrov KC, Standke AK, Bergin IL, Schloss PD, Young VB
- Issue date: 2022 Aug 30

